|Bid||67.78 x 2200|
|Ask||68.63 x 1300|
|Day's range||67.99 - 69.19|
|52-week range||60.89 - 85.97|
|Beta (5Y monthly)||0.66|
|PE ratio (TTM)||N/A|
|Earnings date||22 Oct 2020 - 26 Oct 2020|
|Forward dividend & yield||2.72 (3.99%)|
|Ex-dividend date||14 Sep 2020|
|1y target est||80.17|
Zydus Cadila on Thursday launched the cheapest generic version of Gilead Sciences' antiviral drug remdesivir in India to treat COVID-19 following reports of shortages at hospitals in the world's third-worst hit nation. Zydus has priced it at 2,800 rupees ($37.44) per 100mg vial. It will be sold under the brand name Remdac to government and private hospitals treating COVID-19 patients, the company said in a regulatory filing https://reut.rs/3gTivT4.
The biotech sector remains in focus with earnings, regulatory and other pipeline updates.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...